Desferrioxamine, an iron chelator, enhances HIF-1alpha accumulation via cyclooxygenase-2 signaling pathway.

Cyclooxygenase-2 (COX-2) is an important inducible enzyme in inflammation and is overexpressed in a variety of cancers. Evidence is rapidly accumulating that chronic inflammation may contribute to carcinogenesis through increase of cell proliferation, angiogenesis, and metastasis in a number of neoplasms, including colorectal carcinoma. In the present study, we investigated some mechanistic aspects of DFX-induced hypoxia-driven COX-2 expression. Desferrioxamine (DFX), an iron chelator, is known to upregulate inflammatory mediators. DFX induced the expression of COX-2 and accumulation of HIF-1alpha protein in dose-dependent manners, but hypoxia mimetic agent cobalt chloride (CoCl2) induced accumulation of HIF-1alpha protein but not increase of COX-2 expression. DFX-induced increase of COX-2 expression and HIF-1alpha protein level was attenuated by addition of ferric citrate. This result suggested that the iron chelating function of DFX was important to induce the increase of COX-2 and HIF-1alpha protein. PD98059 significantly inhibited the induction of COX-2 protein and accumulation of HIF-1alpha, suggesting that DFX-induced increase of HIF-1alpha and COX-2 protein was mediated, at least in part, through the ERK signaling pathway. In addition, pretreatment with NS-398 to inhibit COX-2 activity also effectively suppressed DFX-induced HIF-1alpha accumulation in human colon cancer cells, providing the evidence that COX-2 plays as a regulator of HIF-1alpha accumulation in DFX-treated colon cancer cells. Together, our findings suggest that iron metabolism may regulate stabilization of HIF-1alpha protein by modulating cyclooxygenase-2 signaling pathway.

[1]  G. Semenza.  Targeting HIF-1 for cancer therapy , 2003, Nature Reviews Cancer.

[2]  T. Toki,et al.  Desferrioxamine, an iron chelator, upregulates cyclooxygenase-2 expression and prostaglandin production in a human macrophage cell line. , 2001, Biochimica et biophysica acta.

[3]  N. Altorki,et al.  Inhibition of Cyclooxygenase-2 Gene Expression by p53* , 1999, The Journal of Biological Chemistry.

[4]  W. Weichert,et al.  Elevated expression of cyclooxygenase‐2 is a negative prognostic factor for disease free survival and overall survival in patients with breast carcinoma , 2003, Cancer.

[5]  H. Keberle.  The Biochemistry of Desferrioxamine and its Relation to Iron Metabolism , 1964, Annals of the New York Academy of Sciences.

[6]  D. Chaplin,et al.  Microenvironmental control of gene expression: implications for tumor angiogenesis, progression, and metastasis. , 1998, Seminars in radiation oncology.

[7]  J. Marshall,et al.  Hypoxia facilitates tumour cell detachment by reducing expression of surface adhesion molecules and adhesion to extracellular matrices without loss of cell viability. , 1998, British Journal of Cancer.

[8]  Yuichi Makino,et al.  Regulation of the Hypoxia-inducible Transcription Factor 1α by the Ubiquitin-Proteasome Pathway* , 1999, The Journal of Biological Chemistry.

[9]  L. Huang,et al.  Regulation of hypoxia-inducible factor 1α is mediated by an O2-dependent degradation domain via the ubiquitin-proteasome pathway , 1998 .

[10]  R. DuBois,et al.  The role of cyclooxygenases in inflammation, cancer, and development , 1999, Oncogene.

[11]  George M. Hilliard,et al.  Cobalt Inhibits the Interaction between Hypoxia-inducible Factor-α and von Hippel-Lindau Protein by Direct Binding to Hypoxia-inducible Factor-α* , 2003, The Journal of Biological Chemistry.

[12]  J. LaManna,et al.  Hypoxic Regulation of Angiopoietin-2 Expression in Endothelial Cells* , 2004, Journal of Biological Chemistry.

[13]  N. Altorki,et al.  Cyclo-oxygenase 2: a pharmacological target for the prevention of cancer. , 2001, The Lancet. Oncology.

[14]  A. Ristimäki,et al.  Down-regulation of cytokine-induced cyclo-oxygenase-2 transcript isoforms by dexamethasone: evidence for post-transcriptional regulation. , 1996, The Biochemical journal.

[15]  Hyung-Seok Kim,et al.  Correlation between cyclooxygenase-2 and tumor angiogenesis in non-small cell lung cancer. , 2003, Lung cancer.

[16]  T. Fojo,et al.  p53 Inhibits Hypoxia-inducible Factor-stimulated Transcription* , 1998, The Journal of Biological Chemistry.

[17]  J. Simons,et al.  Dibenzoylmethane, a natural dietary compound, induces HIF-1α and increases expression of VEGF , 2003 .

[18]  G. Mann,et al.  Induction of cyclooxygenase‐2 expression in human myometrial smooth muscle cells by interleukin‐1β: involvement of p38 mitogen‐activated protein kinase , 1999 .

[19]  J. Caro,et al.  Hypoxia-inducible factor 1alpha (HIF-1alpha) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions. Its stabilization by hypoxia depends on redox-induced changes. , 1997, The Journal of biological chemistry.

[20]  G. FitzGerald,et al.  The coxibs, selective inhibitors of cyclooxygenase-2. , 2001, The New England journal of medicine.

[21]  A. O'Brien-Ladner,et al.  Differential regulation of human alveolar macrophage-derived interleukin-1β and tumor necrosis factor-α by iron , 1998 .

[22]  J. Simons,et al.  NS398 reduces hypoxia‐inducible factor (HIF)‐1α and HIF‐1 activity: Multiple‐level effects involving cyclooxygenase‐2 dependent and independent mechanisms , 2004, International journal of cancer.

[23]  M. Favata,et al.  Inhibition of MAP kinase kinase prevents cytokine and prostaglandin E2 production in lipopolysaccharide-stimulated monocytes. , 1998, Journal of immunology.

[24]  G. Weiss,et al.  Central role of transcription factor NF-IL6 for cytokine and iron-mediated regulation of murine inducible nitric oxide synthase expression. , 1999, Journal of immunology.

[25]  G. Semenza,et al.  HIF-1 and tumor progression: pathophysiology and therapeutics. , 2002, Trends in molecular medicine.

[26]  R. Wenger.  Mammalian oxygen sensing, signalling and gene regulation. , 2000, The Journal of experimental biology.

[27]  B. Brüne,et al.  Accumulation of HIF-1alpha under the influence of nitric oxide. , 2001, Blood.

[28]  C. Lewis,et al.  Macrophage responses to hypoxia: implications for tumor progression and anti-cancer therapies. , 2005, The American journal of pathology.

[29]  B. Brüne,et al.  Regulation of the Hypoxia-inducible Factor 1α by the Inflammatory Mediators Nitric Oxide and Tumor Necrosis Factor-α in Contrast to Desferroxamine and Phenylarsine Oxide* , 2001, The Journal of Biological Chemistry.

[30]  W. MacNee,et al.  Activation of NF-κB by PM10 Occurs via an Iron-Mediated Mechanism in the Absence of IκB Degradation , 2000 .

[31]  P. Lipsky,et al.  Cyclooxygenase in biology and disease , 1998, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[32]  P. Chomczyński,et al.  Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. , 1987, Analytical biochemistry.

[33]  M. Gassmann,et al.  Oxygen supply and oxygen-dependent gene expression in differentiating embryonic stem cells. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[34]  R. Wenger,et al.  Normoxic induction of the hypoxia‐inducible factor 1α by insulin and interleukin‐1β involves the phosphatidylinositol 3‐kinase pathway , 2002 .

[35]  S. Tannenbaum,et al.  Analysis of nitrate, nitrite, and [15N]nitrate in biological fluids. , 1982, Analytical biochemistry.

[36]  J. Redondo,et al.  Cyclooxygenase-2: a therapeutic target in angiogenesis. , 2003, Trends in molecular medicine.

[37]  K. Webster,et al.  Molecular Regulation of the Endothelin-1 Gene by Hypoxia , 2001, The Journal of Biological Chemistry.

[38]  P. Glazer,et al.  Mutagenesis induced by the tumor microenvironment. , 1998, Mutation research.

[39]  S. Weitzman,et al.  Inflammation and cancer: role of phagocyte-generated oxidants in carcinogenesis. , 1990, Blood.

[40]  A. Levine,et al.  Cyclooxygenase-2 Suppresses Hypoxia-induced Apoptosis via a Combination of Direct and Indirect Inhibition of p53 Activity in a Human Prostate Cancer Cell Line* , 2005, Journal of Biological Chemistry.

[41]  R. Langenbach,et al.  Why there are two cyclooxygenase isozymes. , 2001, The Journal of clinical investigation.

[42]  Hsiu‐Po Wang,et al.  Cyclooxygenase-2 increases hypoxia-inducible factor-1 and vascular endothelial growth factor to promote angiogenesis in gastric carcinoma. , 2005, Journal of biomedical science.